A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Raynaud's disease; Scleroderma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Apr 2017 Primary endpoint has been met. (Change in Digital Blood Flow From Pre- to Post-injection.) as per results published in the Arthritis and Rheumatology
    • 20 Apr 2017 Results published in the Arthritis and Rheumatology
    • 28 Oct 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top